SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
1 Year Est. Return
+115.63%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$2.47B
AUM Growth
+$112M
Cap. Flow
Cap. Flow %
Top 10 Hldgs %
Holding
119
New
Increased
Reduced
Closed

Top Buys

1
+$104M
2
+$63.4M
3
+$63.3M
4
KRYS icon
Krystal Biotech
KRYS
+$56.4M
5
PGNY icon
Progyny
PGNY
+$44.3M

Top Sells

1
+$80.6M
2
+$74.2M
3
+$57.1M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$39M
5
GSK icon
GSK
GSK
+$31.3M

Sector Composition

1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MSLE
76
Satellos Bioscience
MSLE
$127M
$2.33M 0.09%
+414,359
ARWR icon
77
Arrowhead Research
ARWR
$10.2B
$1.79M 0.07%
+28,479
NSPR icon
78
InspireMD
NSPR
$45M
$1.7M 0.07%
1,045,708
-104,292
INSM icon
79
Insmed
INSM
$22.5B
$1.68M 0.07%
10,250
-38,250
CTMX icon
80
CytomX Therapeutics
CTMX
$701M
$1.41M 0.06%
+300,000
CGON icon
81
CG Oncology
CGON
$4.95B
$1.35M 0.05%
20,000
-150,000
NEO icon
82
NeoGenomics
NEO
$1.47B
$1.3M 0.05%
175,000
-252,504
QNRX
83
Quoin Pharmaceuticals
QNRX
$8.9M
$480K 0.02%
72,730
+47,730
COGT icon
84
Cogent Biosciences
COGT
$5.51B
$385K 0.02%
10,000
-110,000
TYRA icon
85
Tyra Biosciences
TYRA
$1.62B
$383K 0.02%
10,000
-115,000
STAA icon
86
STAAR Surgical
STAA
$1.49B
$374K 0.02%
20,000
-5,000
ANAB icon
87
AnaptysBio
ANAB
$1.5B
$333K 0.01%
6,000
-129,000
RAPP
88
Rapport Therapeutics
RAPP
$1.77B
$313K 0.01%
+10,000
RIGL icon
89
Rigel Pharmaceuticals
RIGL
$561M
$270K 0.01%
10,000
-290,034
ZYME icon
90
Zymeworks
ZYME
$1.79B
$250K 0.01%
10,000
-90,000
LBRX
91
LB Pharmaceuticals
LBRX
$802M
$247K 0.01%
10,000
ORKA
92
Oruka Therapeutics
ORKA
$3.76B
$245K 0.01%
5,000
-185,000
JSPR icon
93
Jasper Therapeutics
JSPR
$14.9M
$242K 0.01%
276,312
+76,312
CAPR icon
94
Capricor Therapeutics
CAPR
$1.6B
– –
-646,390
CDTX
95
DELISTED
Cidara Therapeutics
CDTX
– –
-38,811
DCTH icon
96
Delcath Systems
DCTH
$357M
– –
-10,000
DYN icon
97
Dyne Therapeutics
DYN
$2.97B
– –
-10,000
ERAS icon
98
Erasca
ERAS
$4.13B
– –
-2,162,162
FOLD
99
DELISTED
Amicus Therapeutics
FOLD
– –
-5,207,284
GSK icon
100
GSK
GSK
$99.7B
– –
-639,000
1 2 3
4
5